Daejin Abidoje

Daejin Abidoje

Company: Seattle Genetics

Job title: Vice President, Clinical Development


PADCEV: An Evolution in the Therapeutic Landscape of Urothelial Cancer 8:40 am

• Assessing ADCs as a new therapeutic class in bladder cancer and PADCEV’s unique mechanism of action • Analyzing data on efficacy/safety of PADCEV in metastatic urothelial cancer and ongoing exploration of its activity in early bladder cancer • Evaluating PADCEV as an MMAE-class ADC and its potential synergy with immunotherapyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.